
News|Articles|January 17, 2024
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment (January 2024)
Author(s)ZS Associates
Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Related Content
Trending on PharmExec
1
Pharmaceutical Executive Daily: Unpacking IRA-Driven Formulary Pressure
2
President Trump Set to Nominate Heidi Overton as FDA Commissioner
3
When Drug Pricing Becomes Trade Policy
4
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
5